Kadali Srilatha, Radhika Ananthaneni, Kanaka Durga Devi Yadam Reddy, Sreemanthula Jagadeesh Babu, Palakonda Gopi, Hussain Tajamul, Naushad Shaik Mohammad
Yoda Diagnostics Pvt Ltd, 6-3-862/A, Lal Bungalow add on, Ameerpet, Hyderabad, India.
Center of Excellence in Biotechnology Research, King Saud University, Riyadh 11451, Saudi Arabia; Research Chair for Biomedical Application of Nanomaterials, Biochemistry Department, King Saud University, Riyadh 11451, Saudi Arabia.
Clin Nutr ESPEN. 2025 Feb;65:126-133. doi: 10.1016/j.clnesp.2024.11.027. Epub 2024 Nov 26.
Studies have linked the methylenetetrahydrofolate reductase (MTHFR) c.665C > T (rs1801133) with hyperhomocysteinemia. Mandatory folate fortification nullified this association. However, its relevance persists in regions with no folate fortification resulting in a relatively low frequency of this variant in healthy population. This study explored the MTHFR variant's association with 50 clinical manifestations in the absence of folate fortification.
We performed mutation analysis via whole exome and Sanger sequencing in 2431 cases and 1265 healthy controls and the food frequency-based dietary folate intake assessment.
The cohort's average dietary folate intake was 373 ± 141 μg/day. MTHFR rs1801133 variant demonstrated ≥4.49-fold increased risk for respiratory distress, recurrent pregnancy loss (RPL), ischemic stroke, autism, global developmental delay, dysplasia, myoclonic jerks, intellectual disability, aggressive behavior, motor delay, Alzheimer's, cerebellar atrophy, failure to thrive, cerebral atrophy, increased tendon reflexes, and spasticity (p < 0.0001). MTHFR T-allele showed 1.81-4.04 folds increased risk for mental retardation, behavioral problems, dystonia, anemia, gait abnormality, hypotonia, recurrent pneumonia, liver disease, cerebral palsy, short stature, hyperactivity, and cognitive decline. The association of this variant with seizures was moderate (OR: 1.51, 95 % CI: 1.13-2.02, p = 0.009). MTHFR TT-genotype was associated with a 5.81-fold risk for the abnormal phenotype (95 % CI: 1.39-24.28, p = 0.005). MTHFR T-allele was associated with low 25-hydroxy vitamin D, Ferritin, TIBC, and elevated total cholesterol.
The MTHFR rs1801133 increases the risk for RPL, developmental milestones, neuronal development, autism, ischemic stroke, and late-onset neurological functions. The MTHFR TT-genotype is strongly associated with abnormal phenotypes.
研究已将亚甲基四氢叶酸还原酶(MTHFR)c.665C>T(rs1801133)与高同型半胱氨酸血症联系起来。强制性叶酸强化消除了这种关联。然而,在没有叶酸强化的地区,这种关联仍然存在,导致该变体在健康人群中的频率相对较低。本研究探讨了在没有叶酸强化的情况下MTHFR变体与50种临床表现的关联。
我们通过全外显子组测序和桑格测序对2431例患者和1265名健康对照进行了突变分析,并基于食物频率评估了膳食叶酸摄入量。
该队列的平均膳食叶酸摄入量为373±141μg/天。MTHFR rs1801133变体显示呼吸窘迫、复发性流产(RPL)、缺血性中风、自闭症、全面发育迟缓、发育异常、肌阵挛、智力残疾、攻击行为、运动迟缓、阿尔茨海默病(老年痴呆症)、小脑萎缩、生长发育不良、脑萎缩、腱反射亢进和痉挛的风险增加≥4.49倍(p<0.0001)。MTHFR T等位基因显示智力发育迟缓、行为问题、肌张力障碍、贫血、步态异常、肌张力减退、复发性肺炎、肝病、脑瘫、身材矮小、多动和认知衰退的风险增加1.81至4.04倍。该变体与癫痫发作的关联为中等程度(比值比:1.51,95%置信区间:1.13-2.02,p=0.009)。MTHFR TT基因型与异常表型的风险增加5.81倍相关(95%置信区间:1.39-24.28,p=0.005)。MTHFR T等位基因与低水平的25-羟基维生素D、铁蛋白(血清铁蛋白)、总铁结合力以及总胆固醇升高有关。
MTHFR rs1801133增加了复发性流产、发育里程碑、神经元发育、自闭症、缺血性中风和迟发性神经功能的风险。MTHFR TT基因型与异常表型密切相关。